scholarly journals Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children’s Oncology Group Study POG 9421

Leukemia ◽  
2012 ◽  
Vol 27 (3) ◽  
pp. 731-734 ◽  
Author(s):  
M M O'Brien ◽  
X Cao ◽  
S Pounds ◽  
G V Dahl ◽  
S C Raimondi ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Multicenter Trial ◽  
Oncology Group ◽  
Acute Megakaryoblastic Leukemia ◽  
Oncology Group Study ◽  
Megakaryoblastic Leukemia ◽  
Prognostic Features ◽  
Leukemia In Children

scholarly journals Maternal health conditions during pregnancy and acute leukemia in children with Down syndrome: A Children's Oncology Group study

2009 ◽  
Vol 52 (5) ◽  
pp. 602-608 ◽  
Author(s):  
Simona Ognjanovic ◽  
Susan Puumala ◽  
Logan G. Spector ◽  
Franklin O. Smith ◽  
Leslie L. Robison ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Maternal Health ◽  
Acute Leukemia ◽  
Health Conditions ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Children With Down Syndrome ◽  
Leukemia In Children

The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children

2019 ◽  
Vol 138 ◽  
pp. 132-138 ◽  
Author(s):  
Riccardo Masetti ◽  
Vanessa Guidi ◽  
Laura Ronchini ◽  
Nicola Salvatore Bertuccio ◽  
Franco Locatelli ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Acute Megakaryoblastic Leukemia ◽  
Megakaryoblastic Leukemia ◽  
Leukemia In Children

scholarly journals Outcome and Prognostic Features in Pediatric Acute Megakaryoblastic Leukemia Without Down Syndrome

2020 ◽  
Author(s):  
Yu Wang ◽  
Aidong Lu ◽  
Yueping Jia ◽  
Yingxi Zuo ◽  
Jun Wu ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Prognostic Factors ◽  
Induction Therapy ◽  
Residual Disease ◽  
Univariate Analysis ◽  
Poor Response ◽  
Acute Megakaryoblastic Leukemia ◽  
Hematopoietic Stem ◽  
Megakaryoblastic Leukemia ◽  
Prognostic Features

Abstract Background: Acute megakaryoblastic leukemia (AMKL) is a biologically heterogeneous subtype of acute myeloid leukemia (AML) that originates from megakaryocytes. Despite improvements in the accuracy of diagnosing AMKL as well as increased amount of data available on this rare subtype, clear prognostic factors and treatment recommendations remain undefined.Methods: We performed a retrospective study on 40 patients (age ≤18 years) with non–Down syndrome AMKL and assessed the effect of different prognostic factors on the outcomesResults: The complete remission (CR) rate of the patients was 57.9% and 81.1%, respectively, at the end of induction therapy Ⅰ and Ⅱ. The overall survival (OS) and event-free survival (EFS) rate at 2 years was 41±13% and 41±10%, respectively. An analysis of the cytogenetic features showed that patients with +21 or hyperdiploid (＞50 chromosomes) had significantly better OS than those in other cytogenetic subgroups (Plog-rank=0.048 and Plog-rank=0.040, respectively). Besides cytogenetics, an excellent early treatment response (CR and minimal residual disease＜1% after induction therapy Ⅰ) also provided a significant survival benefit in univariate analysis in our study. However, multivariate analysis indicated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) was the only independent prognostic marker (RR=11.192; 95 % CI, 2.045-61.241; P=0.005 for OS and RR=5.400; 95 % CI, 1.635-17.832; P=0.006 for EFS, respectively). Conclusion: AMKL in patients with non-Down syndrome has a poor outcome and allo-HSCT may be a better option for post-remission therapy than conventional chemotherapy especially for those having a poor response to induction therapy.

Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome

2017 ◽  
Vol 56 (5) ◽  
pp. 394-404 ◽  
Author(s):  
Yusuke Hara ◽  
Norio Shiba ◽  
Kentaro Ohki ◽  
Ken Tabuchi ◽  
Genki Yamato ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Prognostic Impact ◽  
Acute Megakaryoblastic Leukemia ◽  
Megakaryoblastic Leukemia ◽  
Molecular Profiles

Acute megakaryoblastic leukemia in Down syndrome: orbital infiltration

2000 ◽  
Vol 130 (1) ◽  
pp. 128-130 ◽  
Author(s):  
Jeffrey L Olson ◽  
Michael J May ◽  
Linda Stork ◽  
Nina Kadan ◽  
J.Bronwyn Bateman
Keyword(s):  
Down Syndrome ◽  
Acute Megakaryoblastic Leukemia ◽  
Megakaryoblastic Leukemia

Acute Megakaryoblastic Leukemia in Children and Adolescents: A Retrospective Analysis of 24 Cases

1993 ◽  
Vol 10 (4-5) ◽  
pp. 299-306 ◽  
Author(s):  
Raul C. Ribeiro ◽  
Maria S.P. Oliveira ◽  
Diane Fairclough ◽  
Craig Hurwitz ◽  
Joseph Mirro ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Retrospective Analysis ◽  
Acute Megakaryoblastic Leukemia ◽  
Megakaryoblastic Leukemia ◽  
Leukemia In Children

scholarly journals Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS)

2014 ◽  
Vol 7 (1) ◽  
Author(s):  
Maria Chiara Pelleri ◽  
Allison Piovesan ◽  
Maria Caracausi ◽  
Anna Concetta Berardi ◽  
Lorenza Vitale ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Acute Megakaryoblastic Leukemia ◽  
Megakaryoblastic Leukemia

Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience

Blood ◽  
2001 ◽  
Vol 97 (12) ◽  
pp. 3727-3732 ◽  
Author(s):  
Uma H. Athale ◽  
Bassem I. Razzouk ◽  
Susana C. Raimondi ◽  
Xin Tong ◽  
Frederick G. Behm ◽  
...  
Keyword(s):  
Down Syndrome ◽  
De Novo ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Transplantation ◽  
Remission Induction ◽  
Allogeneic Bone ◽  
Acute Megakaryoblastic Leukemia ◽  
Free Survival ◽  
Megakaryoblastic Leukemia ◽  
De Novo Aml

To describe the clinical and biologic features of pediatric acute megakaryoblastic leukemia (AMKL) and to identify prognostic factors, experience at St Jude Children's Research Hospital was reviewed. Of 281 patients with acute myeloid leukemia treated over a 14-year period, 41 (14.6%) had a diagnosis of AMKL. Six patients had Down syndrome and AMKL, 6 had secondary AMKL, and 29 had de novo AMKL. The median age of the 22 boys and 19 girls was 23.9 months (range, 6.7-208.9 months). The rate of remission induction was 60.5%, with a 48% rate of subsequent relapse. Patients with Down syndrome had a significantly higher 2-year event-free survival (EFS) estimate (83%) than did other patients with de novo AMKL (14%) or with secondary AMKL (20%;P ≤ .038). Among patients who had de novo AMKL without Down syndrome, 2-year EFS was significantly higher after allogeneic bone marrow transplantation (26%) than after chemotherapy alone (0%;P = .019) and significantly higher when performed during remission (46%) than when performed during persistent disease (0%;P = .019). The 5-year survival estimates were significantly lower for de novo AMKL (10%) than for other forms of de novo AML (42%; P < .001). Treatment outcome is very poor for patients with AMKL in the absence of Down syndrome. Remission induction is the most important prognostic factor. Allogeneic transplantation during remission offers the best chance of cure; in the absence of remission, transplantation offers no advantage over chemotherapy alone.

Sign in / Sign up

Export Citation Format

Share Document